Home > Strands > Deep Innovation > TAU Brain Scholar Wins a $50,000 Alzheimer Research Award Prof. Inna Slutsky is the first Israeli to win the prestigious MetLife Foundation Award for Alzheimer Research

TAU Brain Scholar Wins a $50,000 Alzheimer Research Award Prof. Inna Slutsky is the first Israeli to win the prestigious MetLife Foundation Award for Alzheimer Research

inna-slutsky

特拉维夫大学大脑科学研究者荣膺5万美元阿尔茨海默病研究奖 Prof. Inna Slutsky, head of the Slutsky lab at the TAU Sackler School of Medicine, is the first Israeli researcher to win the prestigious MetLife Foundation Award for Alzheimer Research.

The $50,000 award was presented last week at the Alzheimer’s Association International Conference in Toronto, where Prof. Slutsky was named the most promising investigator.

Prof. Slutsky’s research explores the primary mechanisms initiating synaptic and network dysfunctions in Alzheimer’s disease. In a recent study published earlier this year in Neuron, a group of researchers led by her explored the IGF-1 receptor and its role in the development of Alzheimer’s.

The presence of IGF (Insulin-like Growth Factor) tends to increase with age. According to the authors, an increased activity of IGF-1R at the hippocampal region leads to suppression of spontaneous synaptic release, which may be an explanation for the development of Alzheimer’s disease.

A selective deactivation of IGF-1R may be the basis for development of a prophilactic treatment for cognitive failure, characteristic of Alzheimer’s disease, thus improving the patients’ quality of life.

Watch and read A Novel Approach to Cure Alzheimer’s Disease – a lecture presented by Inna Slutsky at the Deep Innovation workshop organized by CIV.

The Slutsky lab is part of the Sagol School of Neuroscience – an interdisciplinary framework for brain research, integrating researchers and labs from the schools of Medicine, Life Sciences, Social Sciences, Exact Sciences and Engineering.

In a recent Deep Innovation issue of Coller Venture Review, Dr. Dana Bar-On addresses the unique challenges of brain research and innovation. Neuroscience was so far majorly abandoned by big pharma companies, and Dr. Bar-On’s paper discusses new initiatives and innovation models set to bring back industry, government and academia into the complex game of Neuroscience, working together to advance the field and get the search for desperately needed cures back on track.

Read “Deep Innovation and Brain Ventures” – a domain case study published in CVR Issue #3.

Check Also

GoforIsrael Investment Conference 5-Mar-2018 | Hilton Tel Aviv

The Coller Institute of Venture is cooperating with Cukierman & Co. Investment House and Catalyst Fund for …